Clinical trials: HBP
Obesity
A Study of Safety and Efficacy of Topiramate in Male Patients With Abdominal Obesity
The purposes of this study are to compare the effects of Topiramate and placebo on abdominal visceral fat accumulation at 6 months and to evaluate the safety of Topiramate for up to 12 months of continued treatment in male…
- Trial name
- NCT00231608
- Testing
- topiramate
- Volunteers
- 68 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypertension, Pulmonary
An Open Multiple Dose Titration Study In Patients With Pulmonary Hypertension
This is a study to demonstrate the feasibility of an individual dose titration scheme based on the systolic blood pressure with a dose range from 1.0 mg TID to 2.5 mg TID.
- Trial name
- NCT00454558
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 15 sites in Germany
- Volunteers
- 75 people
- Sponsor
- Bayer
Hypertension
A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg
To evaluate the blood pressure lowering effects of the combination of aliskiren 300 mg and HCTZ 25 mg in obese patients with essential hypertension inadequately treated with HCTZ 25 mg, compared to irbesartan or amlodipine with…
- Trial name
- NCT00219115
- Testing
- aliskiren
- Where
- 2 sites in United States, Germany
- Volunteers
- 493 people
- Sponsor
- Novartis
Pulmonary Hypertension, Interstitial Lung Disease
An Open-Label ProSpective MultiCENTer Study to Evaluate Safety and Tolerability of Dry Powder Inhaled Treprostinil in PH
Study LTI-401 is an open-label, multicenter study which will evaluate the safety and tolerability of LIQ861 in subjects who have WHO Group 1 \& 3 PH.
- Trial name
- ASCENT (NCT06129240)
- Testing
- LIQ861
- Where
- 18 sites in United States
- Volunteers
- 80 people
- Sponsor
- Liquidia Technologies, Inc.
Hypertension
The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)
This study will test the relationship between CBP (central blood pressure) and PBP (peripheral blood pressure) effects after single and multiple doses of Isosorbide mononitrate extended release (ISMN ER) or Amlodipine besylate in…
- Trial name
- NCT01130168
- Testing
- Comparator: Amlodipine, Comparator: ISMN ER
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Essential Hypertension
Combination of Olmesartan and Hydrochlorothiazide in Essential Hypertension
The study will evaluate the blood pressure lowering effects of two different dosages of the combination of olmesartan and hydrochlorothiazide in patients with moderate or severe high blood pressure.
- Trial name
- NCT00430950
- Testing
- olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets, olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg
- Where
- 41 sites in Belgium, Germany and 2 more
- Volunteers
- 1,011 people
- Sponsor
- Daiichi Sankyo
Hypertension
A Study to Investigate the Antihypertensive Efficacy of MK0954
After a 4 week placebo period, patients were randomized to Placebo or Losartan 50 mg arms, after 6 weeks non-responders were up titrated to 100 mg losartan for the remaining 6 weeks.
- Trial name
- NCT00887250
- Testing
- losartan potassium, Comparator: losartan
- Volunteers
- 366 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients
This study is designed as a mechanistic study to compare the effect of two different combinations of anti-hypertensive treatments (aliskiren and valsartan vs.
- Trial name
- NCT00939588
- Testing
- Aliskiren/ Valsartan, Telmisartan/ Ramipril
- Where
- Russia
- Volunteers
- 88 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Diabetes Mellitus, Type 2
INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria
A randomized, double-blind, active control trial to determine the safety, efficacy and pharmacokinetics of INV-144 versus losartan potassium plus placebo in subjects with hypertension and Type 2 diabetes mellitus with nephropathy…
- Trial name
- NCT01398423
- Testing
- Active Control, INV-144
- Where
- 19 sites in United States
- Volunteers
- 88 people
- Sponsor
- InVasc Therapeutics, Inc.
Hypertension, Dyslipidemia
Efficacy of Fixed-doses of Antihypertensive and Statin Drugs
The purpose of this study is to evaluate the efficacy of different fixed-dose combination of Viena II in treatment of hypertension and dyslipidemia.
- Trial name
- NCT03401580
- Testing
- Viena II 160/10, Viena II 190/10, Viena II 160/12
- Sponsor
- EMS
Pulmonary Arterial Hypertension
Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy
To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients
- Trial name
- REPLACE (NCT02891850)
- Testing
- Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
- Where
- 81 sites in United States, Austria and 19 more
- Volunteers
- 225 people
- Sponsor
- Bayer
Hypertension
Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension
The primary objective of this trial is to demonstrate that the fixed-dose combination of T80/HCTZ25 is superior as first line therapy in reducing seated trough cuff Systolic Blood Pressure(SBP) compared to the monotherapy of T80…
- Trial name
- NCT00926289
- Testing
- Telmisartan, Hydrochlorothiazide
- Where
- 106 sites in United States, Bulgaria and 6 more
- Volunteers
- 894 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Medication Adherence
Collabree: A Remote Intervention to Improve the Regularity of Medication Intake
This is a clinical study to improve the regularity of medication intake for high blood pressure. Adult women and men who are over 50 years old, who have received a prescription drug for high blood pressure from MediService, and…
- Trial name
- NCT05131074
- Testing
- Collabree Mobile Phone Application Medication Adherence Booster, Collabree Mobile Phone Application Medication Adherence Booster (simplified version)
- Where
- Switzerland
- Volunteers
- 144 people
- Sponsor
- Anjali Raja Beharelle
Essential Hypertension
Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension
To investigate the efficacy and safety of azilsartan compared to olmesartan medoxomil in patients with grade I or II essential hypertension
- Trial name
- NCT02407210
- Testing
- azilsartan, Olmesartan medoxomil
- Where
- China
- Volunteers
- 304 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Glaucoma
Evaluating the Efficacy and Safety of Xalost S in Glaucoma Patients.
In patients with Glaucoma, Xalost S or Xalatan or Taflotan-S are administered for 12 weeks. After 12 weeks, among them, Xalatan administration group are switched to Xalost S or Taflotan-S. Extension study period is 8 weeks.
- Trial name
- NCT04164459
- Testing
- Xalost S, Xalatan, Taflotan-S
- Where
- South Korea
- Volunteers
- 144 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Hypertension Associated, Type II Diabetes Mellitus
Efficacy and Safety of Atenas Association in the Treatment of Type II Diabetes Mellitus and Hypertension
The purpose of this study is to evaluate the efficacy and safety of Atenas association in the treatment of type 2 diabetes mellitus and hypertension
- Trial name
- ATENAS (NCT05144360)
- Testing
- Atenas
- Sponsor
- EMS
Hypertension
A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers
The purpose of this clinical trial is to evaluate the pharmacokinetics and the safety after administration of "BR1015" and co-administration of "BR1015-1" and "BR1015-2" under fed conditions in healthy volunteers
- Trial name
- NCT06008015
- Testing
- BR1015, BR1015-1, BR1015-2
- Where
- South Korea
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hyperlipidemia, Hypertension
Efficacy and Safety Study of YH16410 Versus Rosuvastatin and Telmisartan Monotherapies in Patients With Hypertension and Hyperlipidemia
To evaluate efficacy and safety of YH16410 versus rosuvastatin and telmisartan monotherapies in patients with hypertension and hyperlipidemia
- Trial name
- NCT01914432
- Testing
- YH16410, Rosuvastatin, Telmisartan
- Where
- South Korea
- Volunteers
- 210 people
- Sponsor
- Yuhan Corporation
Hypertension
VALENCE: Valsartan Versus Atenolol on Exercise Capacity in Hypertensive Overweight Postmenopausal Women
The purpose of the study is to show that valsartan compared to atenolol has favorable effects on exercise capacity, quality of life, diastolic function and elevated blood pressure in hypertensive postmenopausal overweight women…
- Trial name
- NCT00171132
- Testing
- valsartan, atenolol, hydrochlorothiazide
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 64 people
- Sponsor
- Novartis
Hypertension, Type 2 Diabetes
Multi-Organ Denervation With the iRF System to RedUce Sympathetic Drive
The objective of the study is to evaluate the safety of multi-organ denervation using the Integrated Radio Frequency (iRF) Denervation System. and to understand any potential improvement in hypertension and glycemic control.
- Conditions
- Hypertension, Type 2 Diabetes, Metabolic Syndrome
- Trial name
- MODUS (NCT04917393)
- Testing
- iRF System Multi-organ Denervation, Control Procedure
- Where
- 2 sites in Georgia
- Volunteers
- 45 people
- Sponsor
- Metavention
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.